Seelos Therapeutics, a clinical-stage biopharmaceutical company, has announced a registered direct offering of 380,968 shares of common stock at a price of $2.46 per share, alongside pre-funded warrants to purchase up to 81,239 shares of common stock at $2.459 per warrant. The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable upon issuance. Additionally, Seelos is offering the shares of common stock issuable upon the exercise of the pre-funded warrants. The offering is being made directly to investors with Roth Capital Partners, LLC acting as the exclusive placement agent. The placement agent has agreed to use reasonable best efforts to sell the securities offered. The offering is expected to close on or about May 21, 2024, subject to customary closing conditions. The net proceeds, estimated at approximately $0.9 million after deducting fees and expenses, will be used to repay a portion of the principal and accrued interest under an outstanding convertible promissory note and for general corporate purposes. The common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL.'

Seelos Therapeutics, a clinical-stage biopharmaceutical company, has announced a registered direct offering of 380,968 shares of common stock at a price of $2.46 per share, alongside pre-funded warrants to purchase up to 81,239 shares of common stock at $2.459 per warrant. The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable upon issuance. Additionally, Seelos is offering the shares of common stock issuable upon the exercise of the pre-funded warrants. The offering is being made directly to investors with Roth Capital Partners, LLC acting as the exclusive placement agent. The placement agent has agreed to use reasonable best efforts to sell the securities offered. The offering is expected to close on or about May 21, 2024, subject to customary closing conditions. The net proceeds, estimated at approximately $0.9 million after deducting fees and expenses, will be used to repay a portion of the principal and accrued interest under an outstanding convertible promissory note and for general corporate purposes. The common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL.'